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Crystal formation reflects the entire composition of the surrounding solution. In case of urolithiasis, induced crystal
formation in native urine has led to the development of the Bonn-Risk-Index (BRI), a valuable tool to quantify an
individual's risk of calcium oxalate urolithiasis. If the progression of a disease is associated with characteristic changes in
the activities of urinary components, this leads to an altered urinary crystallisation capacity. Therefore, the results
of induced urinary crystal formation can be used to detect and monitor any disease linked to the altered urinary
composition. Since crystal formation inherently takes into account the entire urinary composition, the influence of
the disease on individual urinary parameters does not have to be known in order to monitor the consequent
pathologic alterations. In this paper, we review the background of urinary crystal formation analysis and describe
its established application in urolithiasis monitoring as well as potential further fields of clinical application.
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Theoretical considerations on crystal formation in vivo
Crystal formation from a solution in vivo (in the body,
temperature and pressure are considered to be constant)
is governed by the system's free enthalpy G. The differ-
ence upon crystallisation of the free enthalpy ΔG of a
component, which can exist in crystalline and dissolved
state, can be described as [1]
G ¼ Gx − Gs ¼ − RT ln aa0
 
ð1Þ
with Gx and Gs as the free enthalpies of the component in
the crystalline and dissolved state, respectively. R and T
are the universal gas constant (8.314 JK−1 mol−1) and ab-
solute temperature, respectively. The ratio (a/a0) describes* Correspondence: n.laube@deutsches-harnsteinzentrum.de
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unless otherwise stated.the degree of saturation, whereas a and a0 are the compo-
nent's activity in the solution and the respective activity at
saturation level given by the solubility product. It is an es-
sential condition for a crystal to form and grow that the
solution is supersaturated with respect to the precipitating
phases, i.e. a/a0 > 1. In terms of free enthalpy, supersatur-
ation is described by
G < 0 ð2Þ
the more negative ΔG, the higher the thermodynamic
driving force for precipitation.
Non-specific ion-water and ion-ion interactions of
electrostatic nature between the dissolved constituents
cause ions to behave in a non-ideal manner. This non-
ideal behaviour is reflected by introducing ‘activities’ in-
stead of ‘concentrations’, whereby the activity ai of a
component i (ion or molecule) results from
ai ¼ ci⋅γz ð3Þtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nent i and γz as the mean activity coefficient for the
solution's constituents with charge number z (γz ≤ 1 in
‘real solutions’, γz = 1 in ‘ideal solutions’). The value of γz
reflects the entire interactions of an ion or molecule
with all other components of the solution. Thus, γz is a
measure of how much an actual system deviates from an
ideal system providing the ‘effective concentration’ or
‘availability’ of a particular solute. Only for those ions
analytically accessible by selective electrodes can a be
directly determined. For all other components, γz must
be approximated by empirically derived formulae, which






In urines, I typically ranges between 0.2 and 0.4 mol/l;
therefore, γz can be estimated according to the Davies
equation, an empirical extension of Debye-Hückel the-
ory, which is applicable up to I = 0.5 mol/l [2,3]:
log γz







where A is the Debye-Hückel constant, which is a func-
tion of the temperature and dielectric constant of the so-
lution (A = 0.5211 for H2O at T = 37°C). Ionic strength
plays a central role in ionic activities, since in the range
of validity, γ decreases as I increases.
According to the DLVO theory, ionic strength also in-
fluences the formation of agglomerates as I influences
the thickness of the repulsive ‘diffuse electrical double
layer’, which evolves from the charge of the colloid par-
ticle. At low ionic strength, the repulsive electrostatic
forces of the double layer exceed the attractive Van der
Waals force, and the resulting repulsion between the
particles prevents them from agglomeration (unless the
particle is nearly electrically neutral, which happens at
the pH value of the ‘isoelectric point’). With increasing I,
the likelihood of agglomeration increases [4].
Equations 1–5 show that crystal formation is sensitive
to any ionic constituent coexisting in the surrounding
solution. Changes in the solution's composition thus po-
tentially take significant influence on the precipitation
probability of a particular mineral phase.
Factors affecting urinary crystal and stone formation
As described above, supersaturation is a prerequisite for
the primary and secondary processes of crystal/stone
formation taking place (inter alia, prenucleation cluster
formation, nucleation, crystal growth and aggregation);
its degree influences the respective process rates.The complexity of salt formation from urine and
urine-like solutions is well illustrated by the large num-
ber of different minerals found in uroliths and grown
from these liquids (Figure 1) [5-14]. As the thermo-
dynamic stability fields of these minerals partly overlap
(e.g. pH range in which they show low solubility), they
may form in association with others, i.e. in paragenesis
(Figure 2). Around 60% of uroliths are binary or ternary
mixtures of different minerals [15]. In some cases, a
primarily precipitated but thermodynamically metasta-
ble mineral phase can transform (stepwise) into a more
stable phase (Ostwald's rule), e.g. weddellite→whewel-
lite (Figure 3), brushite→ octacalciumphosphate pentahy-
drate→whitlockite→ apatite and uric acid dihydrate→
uric acid monohydrate.
A number of factors affect urinary supersaturation,
including solute concentration and complexation, ionic
strength, pH value and the presence of promoters
(augmenting the rate of a chemical reaction) or inhibi-
tors (diminishing the rate of a chemical reaction).
These factors vary during the day depending on fluid
intake, dietary intake and body metabolism. Urine in
normal individuals is often supersaturated with respect
to Ca oxalate, Ca phosphate and Na urate and has to
be considered in general as a metastable solution
prone to precipitate upon small changes in compos-
ition or in surface properties (e.g. suspended particles
acting as crystallisation nuclei or urothelium rough-
ness). In fact, urolith formation is strongly influenced
by a multitude of different substances [16-18], e.g.
acid-rich urinary proteins [19], citrate [20,21], magne-
sium [22], osteopontin [23-25], Tamm-Horsfall protein
[26-28], polycarboxylic acids [29,30], copolymers of
polyacrylic acid [31], phosphonates [32] or even ‘un-
identified biomacromolecules’ [33].
Furthermore, protein concentrations (e.g. Tamm-Horsfall
protein [THP], osteopontin, prothrombin fragment 1,
albumin) and crystallographic variables (e.g. crystal de-
fects, as they provide charged surface sites) may influ-
ence interfacial mineral-protein bonding and thus, e.g.
by specific polyanion-crystal interactions, agglomer-
ation of microcrystals and crystal habit [34-37].
The influence of minor urinary components must not
be underestimated. Small concentrations of contaminants/
impurities (e.g. foreign ions, mucoproteins built in the
crystal structure during growth) can lead to a modified
habit (Figures 4 and 5) changing the growth rate (crystal
poisoning) and may have an overproportional impact on
crystal formation. Inhibitors from, inter alia, the group
of bisphosphonates (used in osteoporosis treatment),
proteins and polycarboxylates can show a significant
impact on crystal formation at concentrations in the
order of magnitude of 1 ppm [38-41]. However, it will
be impossible to determine the concentrations of all
Figure 1 Examples of mineral phases found in mammalian uroliths and insoluble salts precipitating from wastewater (after induction
by e.g. pH rise or addition of Mg2+) in the course of recovery of nutrients, such as phosphorus and nitrogen. Formulae represent ideal
stoichiometric compositions. The actual compositions may differ, among others, due to partial substitution, e.g. of Ca2+ with Mg2+ or Fe2+ and
(NH4)
+ with K+.
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within their specific chemical formation environment.
To investigate the different mechanisms of urinary stone
formation and to gain more insight into the individual role
of urinary constituents with respect to supersaturation and
other physicochemical considerations, numerous types ofin vitro experiments with different approaches of chemical
engineering to control, inter alia, the course of supersatur-
ation are established to mimic various aspects of the
(assumed) in vivo situation [37,43]. The more a native
urine sample is supersaturated with respect to a par-
ticular mineral phase, the more easily the system can
Figure 2 SEM picture of urinary crystals found in the native sediment of a filtered 24-h urine of a repeatedly ‘mild hypercalciuric’ but
non-stone-forming proband (pore size 0.45 μm, urinary pH = 5.81, nitrite positive, calcium excretion = 5.9 mmol/day). Rosette-shaped
calcium phosphate (left) coexists with rod-like struvite (mid) and bipyramidal calcium oxalate (right). The morphology-based analysis is confirmed
by elemental analysis using SEM-linked energy-dispersive X-ray spectroscopy.
Figure 3 Internal transformation processes may influence stone
shape. Left: Photograph of a mulberry-shaped urolith composed of
whewellite with numerous facetted growth zones. Right: Thin
section showing pseudomorphs of whewellite crystals in weddellite
shape causing the mulberry-shaped surface of whewellite stones.
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urinary supersaturation.
Why investigating crystal formation in urine?
Crystal growth induced in native urine is a promising
approach to quantify a disease's progression or a treat-
ment's success. As urine composition reflects a person's
metabolic state, medical conditions as well as medical
treatments affecting at least one metabolic process can
be detected by their specific urinary metabolic product
(Figure 6). However, quantification of such a ‘biochem-
ical signal’ by laboratory analysis, if known at all, can be
expensive and time-consuming. In contrast, specifically
induced formation of an appropriate mineral species
from native urine skips the problem of unknown disease
markers and reduces the analysis-related costs.
If a disease state is related to an altered urinary com-
position prone to form a particular type of crystals, the
actual formation of these crystals can be easily triggered
by rising supersaturation of this mineral phase by, e.g.
addition of a promotoric substance to a urine sample. In
a first approach, it can be assumed that the amount of
added trigger substance is a function of the health state.
Therefore, induced crystal formation can be regarded as
a sum parameter for ‘downstream monitoring’ of meta-
bolic diseases. In a second step of ‘upstream analysis’, the
substances assumed to significantly influence crystal for-
mation can be identified by targeted substance-specific
urinalysis.
Any individual is biologically and sociologically unique
and thus reacts differently to exogenous factors in caseof a disease, disorder or medical condition, in particular
to therapeutic measures. It is of interest to measure the
individual response in order to optimise the patient-
focused treatment as well as to establish strategies for a
therapeutic differentiation according to obtained patient
groups. The individual reaction of a patient to a thera-
peutic measure affects urine composition and thus is in-
tegrally included in the crystal formation behaviour. By
patient stratification, associations and interactions of risk
factors as well as of anamnestic and diagnostic informa-
tion can be evaluated for discrimination of therapy re-
sponder vs. non-responder. In contrast, evaluation of
Figure 4 Optical and SEM images of calcium oxalate crystals found in native urinary sediment (crystal sizes range between ≈ 20 and
≈ 35 μm). Besides the typical whewellite crystals in egg, hour glass and barbell shapes and characteristic letter envelope shapes (tetragonal
bipyramids) of weddellite crystals, numerous other crystal habits can be observed. Besides dodecahedrons of weddellite crystals, longitudinal-oval
plates and mulberry habits of whewellite and twinnings also occur as well as characteristically ‘constricted’ whewellite crystals in oval shape. The
simultaneous occurrence of egg, hour glass and barbell shapes at whewellite crystals can be attributed to their typically (deepened) bi-concave
barbell shape. The existence of numerous habits of a mineral phase can be explained by different supersaturation conditions, diffusive processes
and adsorption processes of foreign ions (e.g. [Mg2+], [P2O7]
4−, [C6H5O7]
3−) on preferred crystal surfaces thereby (potentially) inhibiting or
promoting the growth rate of a particular crystallographic direction, which eventually leads to crystals showing different morphologies.
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trol parameters of metabolic diseases (and occasionally
combining them to risk indices) is often ineffective,
complicated, costly and time-consuming.
Risk indices
Risk indices are indicators which facilitate the choice of
an appropriate therapy for the individual patient based
on laboratory data and epidemiological observations. A
risk index classifies the health status of the examined
person with respect to the investigated disease on a stan-
dardised scale. It can be translated into an individual risk
for the person to contract the disease. This way, a risk
index transforms an otherwise unmanageable amount of
data into useful information for decision-making. RiskFigure 5 SEM images of pathological urinary sediments of highly recu
crystals systematically grown together (twinning). Right: Multiple interpeneindices can be used to characterise a patient's base line
risk and to monitor the success of the prescribed treat-
ment scheme.
Risk indices in urolithiasis
Patients developing a disease despite the fact that all of
their individual laboratory parameters lie in their re-
spective normal range are a common challenge in every-
day practice. Most stone formers are idiopathic, i.e.
there is no single quantity indicating their disease, be-
cause stone formation is mainly caused by a complex
imbalance between all promoting and inhibiting urinary
factors [46,47].
In these cases, combination of the excretion values of
several lithogenic and other promotory and inhibitoryrrent CaOx stone patients. Left: Microlith composed of whewellite
trating weddellite twins indicate a lack of inhibitors of crystal growth.
Figure 6 Urine composition reflects the individual interplay of all extrinsic and intrinsic risk factors as well as all metabolic processes
including affected cell and organ functions. Depending on the medical condition, concentrations of particular urinary constituents can
systematically change, and consequently, crystal formation processes are influenced. Therefore, the disease's urinary ‘signal’ can be detected by
induced growth of a particular mineral phase. This relation can be used as a clinical ‘early-warning system’ if the differences in crystal formation
risk and health state are analytically significant. The crystal formation risk can be detected by either continuous increase of urinary supersaturation
(i.e. addition of an appropriate trigger substance) up to the moment of crystal formation (e.g. [44]) or incrementally using preset risk levels (i.e.
discrete amounts of a trigger substance) that are exceeded if crystal formation takes place (e.g. [45]).
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24-h volume and pH value, to multiparameter ratios or
other mathematical expressions, can improve the diag-
nostic information and facilitate therapeutic decision-
making. As these approaches account for the antagonis-
tic processes involved in urinary stone formation, theypromise better distinction between stone formers or per-
sons prone to form stones on the one hand and normal
subjects or successfully treated former stone patients on
the other hand.
Based on urinalysis parameters, simple quotients with
promotory variables in the numerator and inhibitory
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indices exists [48-51]; examples are the concentration
ratios of calcium, citric acid, oxalic acid and magnesium
[Ca]/[CA] and ([Ca] [OA])/([CA] [Mg]).
A prominent example of a more complex risk index for
calcium oxalate, the most common mineral in urinary
stones [52], is the AP(CaOx) index. Tiselius developed it
as an analytical, non-iterative approach to approximate
the ion-activity product with respect to calcium oxalate
from urinalysis data [53]. AP(CaOx) combines the most
influencing parameters into a quotient according to the
results obtained from the calculations [54]:
AP CaOxð Þ ¼ 1:9 Caf g
0:84 OAf g
CAf g0:22 Mgf g0:12V 1:03 ð6Þ
with {Ca}, {OA}, {CA}, {Mg} and V as the urinary 24-h ex-
cretions of calcium, oxalic acid, citric acid and magnesium
and the 24-h urine volume, respectively. The different ex-
ponents in Equation 6 reflect the different influences of
each of the quantities on the ion-activity product and thus
on calcium oxalate formation. The exponents as well as
the prefactor were continuously adjusted to improve the
approximation to the updated calculations of ion-activity
products.
However, despite the manageable number of laboratory
parameters and the use of excretion values (instead of the
thermodynamically more reasonable concentration values)
as commonly accepted by clinicians for evaluation of the
patient's metabolic state, AP(CaOx) is often considered
too ‘cryptic’ and thus only rarely applied.
Another type of risk indices is based on computer sim-
ulations of commonly accepted thermodynamic equilib-
rium models of complex chemical interactions in urine,
taking into account the most important urinary compo-
nents. The simulations iteratively calculate the ion activ-
ities and the concentrations of potentially formed
coexisting complexes from an initial chemical analysis of





3−], [CA], [OA]) and
finally the relative supersaturations and saturation index
for (all) potentially precipitating salts. Computer pro-
grams providing these features include EQUIL [55,56]
and JESS [57-59].
Although these classic thermodynamic approaches
promise the best results for estimation of urinary super-
saturation from urinalysis by including a large number
of urinary components (23 at the most enhanced pro-
gram version, EQUIL93 [55]), it seems that this variety
of input variables and the efforts and time required to
obtain the result hinder, like for AP(CaOx), a more
widespread use of the EQUIL and JESS tools.The Bonn-Risk-Index-approach
Salt-forming components of naturally occurring uroliths
are analytically accessible, and empirically derived algo-
rithms (see above) were developed allowing for calcula-
tion of the activity product to estimate the urolithiasis
risk. However, similar urinary compositions with respect
to major components can show quite different patho-
logical patterns in vivo. Furthermore, about 70% of stone
formers are considered idiopathic, i.e. metabolic diseases
like renal tubular acidosis or hyperparathyroidism as
well as anatomical causes, like ureteral stenosis, can be
excluded and urinalysis does not show (significant)
abnormalities.
Unidentified but influencing constituents and unpredict-
able ‘Dr. Jekyll and Mr. Hyde’ behaviour of known sub-
stances complicate the evaluation of a ‘real’ crystallisation
risk even on the basis of the most detailed urinalysis. In
particular, the role of (intra-crystalline) macromolecules
(mainly proteins, also lipids and carbohydrates), which
form an organic matrix in uroliths comprising in total
2%–10% of the stone's total weight, remains disputable as
they may be either inhibitors or promoters or ‘bystanders’
of stone formation [60-63]. In fact, the physicochemical
properties (e.g. protein structure, ionic charge) and there-
fore the effects of a particular urinary constituent are
dependent on the entire chemical environment (e.g. ionic
strength).
To overcome the drawbacks of analyses based on
selected urinary parameters, a non-specific test was de-
veloped including all urinary constituents to an effect-
directed (‘downstream’) analysis by controlled induction
of urinary calcium oxalate crystal formation combined
with an individual test of an ‘unequivocally crucial and
easy-to-determine’ single parameter, the concentration
of ionised calcium [Ca2+]. The amount of ammonium
oxalate (Ox2−) required to induce formation of CaOx
crystals (originally) in a 200-ml sample of native 24-h
urine or 2 × 12-h urine (e.g. comprising a night and a
day fraction, each lasting 12 h) and [Ca2+] are used to





A scale of eight BRI levels was developed to determine
the risk of CaOx urolithiasis [64]. The BRI shows super-
ior diagnostic sensitivity and specificity compared to
other urolithiasis risk indices [65].
Many diseases are lacking a simple, easily accessible
and cost-saving diagnostic approach to routinely moni-
tor the disease's path and treatment success. Since crys-
tal formation in general and the BRI in particular take
into account every constituent of native urine, they can
be used to monitor a wide range of metabolic diseases. If
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be used for a fast initial diagnosis before the beginning
of therapy and for accompanying diagnostics for deci-
sion support to find a patient-tailored therapy.
The BRI can be determined either manually in a bio-
chemical laboratory or in a fully automated benchtop
measuring device, the Urolizer®. Currently, a microflui-
dic device to estimate the BRI (BRI-on-Chip) is under
development [45]. Different reaction channels containing
appropriate chemicals will indicate the BRI class of a small
urine sample as ‘low’, ‘medium’ or ‘high’ risk of calcium ox-
alate urolithiasis. The result will be displayed by a colour
reaction to be read out by the naked eye or using a port-
able (true point-of-care) diagnostic tool like, for example,
a smartphone app for quantification [66,67]. Therefore,
the BRI-on-Chip will take BRI determination from specia-
lised laboratories to the resident doctor's cabinet or even
to the patient's home upon the doctor's advice.
This way, the effects of, for example, different dietary
concepts like the actual influence of e.g. sodium chlor-
ide, protein and calcium intake on an individual's urin-
ary Ca excretion and the effect of counter measurements
can be tested by the patient on an individual level under
real-world physiological conditions (everyday activities,
travel, exercise and food consumption) in due time.Application potential
Urolithiasis The BRI has proven its qualities as a diag-
nostic tool in the treatment of calcium oxalate urolithia-
sis. Urolithiasis is a widespread ailment in developed
countries with current prevalence rates above 5%. Stone
formation is the result of an altered urinary composition,
mostly caused by a congenital or acquired underlying
metabolic disease (or at least a predisposition to it) and by
triggering exogenous risk factors. This makes the patho-
genesis in each patient unique and diagnosis, causal treat-
ment and therapeutic monitoring difficult, costly and
time-consuming. Routine diagnostic workup is charac-
terised by a lack of analytical results easy to interpret for
clinical decision-making and by weak financial incentives.
The consequence is a diagnostic and therapeutic under-
supply, which inevitably results in a vicious circle of recur-
rent stone formation, although the recurrence rate can be
lowered from 80% without metaphylaxis down to 20%
under risk-adopted therapy (Figure 7).
A strategic shift from ‘disease care’ (i.e. repeated cost-
intensive and side effect beset ‘stone removal only’) to
‘health care’ by individualised recurrence prevention could
be achieved by providing adequate diagnostic tools. A
point-of-care device like the BRI-on-Chip to measure uro-
lithiasis risk by induced urinary crystal formation might
be used for screening (for prophylaxis, e.g. children with a
parent suffering from recurrent urolithiasis or chronicrenal disease) and as a test for individual adjustment and
effective control of metaphylaxis.
Induced crystal growth in urine can be a powerful strat-
egy not only in urolithiasis therapy but also for a wide
spectrum of diseases affecting metabolism (Figure 8), ei-
ther to identify chronically altered or changing renal clear-
ance patterns associated with metabolic diseases, or for
targeted evaluation of the overall influence of therapeutic
measures, including dietary habits (i.e. treatment success).
In the following paragraphs, some diseases known to
affect renal handling and to augment crystal formation
risk are presented, which might benefit from BRI-like ana-
lyses of induced urinary crystal formation.
Osteoporosis Bone constitutes the largest depot of
calcium in the human body. Osteoporosis describes the
loss of bone mineral density and is associated with an
increased risk of fractures, especially in the spine, hip and
wrist. The decrease in bone mineral density is a hormo-
nally regulated, mostly age-related process. Typically, post-
menopausal women are prone to suffer from the disease,
but other reasons like inactivity, medication or hormonal
dysregulation can also be associated with osteoporosis.
While degradation products of bone resorption, such as
calcium and the c- and n-terminal collagen crosslinks, are
currently used as indicators for osteoporosis, neither ele-
vated calcium levels nor the presence of c- and n-terminal
collagen crosslinks (CTX/NTX) in urine is a sufficiently
sensitive diagnostic parameter. Furthermore, measurement
of CTX/NTX is only available in specialised laboratories.
We assume that changes in bone turnover due to osteo-
porosis and other bone-related diseases alter the urinary
stone formation risk. Thus, it would be possible to correlate
BRI results with the results of bone mineral density scans,
bone turnover markers and fracture rate to determine
its value in predicting and monitoring increased bone
resorption and success of the medical treatment.
Risk of immobility-related changes in metabolism
and bone loss A significantly increasing BRI-based crys-
tallisation risk, e.g. of calcium oxalate or uric acid dihy-
drate, while bedridden would allow for early identification
of patients prone to form osteoporotic and nephropathic
disease patterns and timely initiation of preventive mea-
sures (e.g. Ca supplementation, vitamin D, allopurinol).
The individual effect of prevention or countermeasures
can be evaluated as at ‘overdosage’, and the risk of calcium
oxalate crystal formation concomitantly increases again.
Therefore, the individual Ca requirement can be evaluated.
Metastatic malignancies Bone metastases from solid
tumours (e.g. prostate cancer) might be detected earlier
if urinary crystal formation is regularly used to monitor
short-term changes in bone mineral balance. Few studies
Figure 7 The role of the BRI-test in the prevention of recurrent stone formation. Left: The vicious circle of recurrent stone formation as a
result of lacking metaphylactic measures. Right: The BRI has been proven to be a straightforward and intuitive diagnostic tool helping to escape
from therapeutic undersupply and to achieve health and therapy control.
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Assumedly, there is a correlation due to an increase of
crystallisation promoters by metabolic/paraneoplastic
factors or elevated bone turnover following low bone
density or bone metastases. (Hyper-)calciuria, a commonFigure 8 Examples of disease patterns affecting renal function or urin
respect to a particular salt can be specifically and significantly altered comppromoting factor of urinary calculi, was described to be
a diagnostic criterion in hormonal therapy of metastasis-
ing breast carcinoma. Hypercalciuria was also found in
adenocarcinoma of the lung. Without reference to meta-
bolic or laboratory details, the association between someary composition. The resulting urine's crystal formation risk with
ared to that of a healthy subject.
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ney cancer, squamous cell carcinoma of the urinary tract
or ameloblastoma [68-72]. Gawade et al. [73] described
older survivors of childhood acute lymphoblastic leukae-
mia with low bone density to be at risk for renal stones.
Camacho et al. [74] observed hypercalciuria as a second-
ary cause of bone loss in 15.6% of breast cancer patients.
Diabetes mellitus A premature detection of early stages
of nephropathy development might be achieved due to a
rise in glomerular loss of macromolecular blood compo-
nents (e.g. impaired creatinine clearance, proteinuria [e.g.
albumin, THP]) and altered biomarker patterns related to
a progressive course of renal insufficiency. The correlation
between urinary crystal formation risk and potential de-
velopment of secondary complications or co-morbidities
in patients diagnosed with DM should be investigated.
Progressive diabetic nephropathy is characteristic in about
60% of DM patients. Complementary to the BRI technol-
ogy, blood samples should be investigated for potentially
increased metalloproteinase activity as an independent
biomarker for tissue remodelling which accompanies a de-
velopment of diabetic complications (proliferative retino-
and nephropathy). An increased predisposition to urinary
stone formation and extensive tissue remodelling are con-
sidered as the optimal biomarker panels for early predic-
tion of severe DM complications.
Nephropathies No other organ is more involved in
metabolic processes than the kidney. Thus, it is no sur-
prise that (non-diabetes-related) nephropathies [75] go
along with metabolic disorders, partially with an increase of
crystallisation promoters or, more generally, nephropathy-
related specific changes in urinary composition. For ex-
ample, hypercalciuria was described in Bartter's syndrome
or renal sarcoidosis. Minimal change in nephrotic syn-
drome can result in focal calcification and hypercalciuria
[76-78]. Praga et al. [79] found a high prevalence of hyper-
calciuria and nephrolithiasis in patients with thin basement
membrane nephropathy.
Prevention of drug-induced crystal nephropathies
Chronic intake of xenobiotics including a wide variety of
drugs can have side effects which result in specific alter-
ations of urinary composition. These alterations may
cause a significantly increased risk of abnormal crystalluria
(syn. microlithiasis) and urolith formation by, inter alia,
drug-induced hypercalciuria (e.g. loop diuretics, glucocor-
ticoids, vitamin D, calcium supplementation), hyperoxa-
luria (e.g. antibiotics, pyridoxilate), hyperuricosuria (e.g.
uricosurics, chemotherapeutic agents) or unfavourable
changes in urinary pH value (e.g. alkali citrates, Na bicar-
bonate, antacids). Depending on dose and duration of
treatment, oxalates, Ca phosphates, uric acid dihydrate orurates can precipitate. Furthermore, the non-metabolised
drugs themselves or their less-soluble metabolites can
form urinary crystals (e.g. protease inhibitors) [80-84]. Pa-
tients, requiring (high-dose) long-term treatment with po-
tentially nephropathy-inducing drugs, thus may profit
from early recognition of an increased likelihood of intra-
renal crystal precipitation by regular easy-to-perform
monitoring of their urolithiasis risk. At significant changes
in that parameter, prophylaxis and metaphylaxis measure-
ments (e.g. control of individual drug response and dose
effects, dosage adjustment, pH adjustment, adequate hy-
dration) can be initiated at a very early stage.
Therapeutic drug monitoring Medications with a nar-
row therapeutic range and for which target concentrations
are difficult to monitor (i.e. critical dose drugs, e.g. Aciclo-
vir, Digoxin, Lithium, Methotrexate) have to be carefully
supervised [85]. The more the patient shows risk factors
(e.g. age, body mass index, organ function, concomitant
drug therapy) and morbidities (e.g. hepatic diseases, ne-
phropathies, cardiac insufficiencies, diabetes mellitus), the
more important is the finding and dynamic adjustment of
the optimal, i.e. individual, dosage regimen. Investigation
of urinary crystallisation risk targeting on the drug itself
or at a specific drug-related metabolite instead of e.g. ana-
lysis of plasma drug concentration can be a cost-effective
alternative.
Outlook The approach introduced above may serve as
the ‘proof-of-principle’ technological platform for a broad
spectrum of clinical applications. By development of a
simple crystallisation test device (BRI-on-Chip) with one
individual indication-adopted preset ‘cut-off ’ value, or with
multiple graduated cut-off values combined in one set, the
analysis of induced urinary crystallisation can be taken
from specialised laboratories to the doctor's office or even
the patient's home.
In the long term, the analytical method of induced
crystal growth might be transferred to other body liquids
like cerebrospinal fluid or synovial fluid, thereby opening
further application fields for the BRI approach.
For the practical realisation of the approach, a series of
large-scaled multidisciplinary studies might be useful for
international validation and clinical adaptation. In order to
create the appropriate international partnerships within the
field, the new European programme ‘Horizon 2020’ may be
considered. The complete overview of the strategies and
instruments of Horizon 2020 is provided by the ‘Predictive,
preventive and personalised medicine as the hardcore of
“HORIZON 2020”: EPMA position paper’ [86].
Conclusions
The BRI-on-Chip rapid test under development can be
an effective screening and diagnostic tool for many
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http://www.epmajournal.com/content/5/1/13metabolic diseases by induced urinary crystallisation. As
any urinary constituent influences the proneness to crys-
tal formation (and the characteristics of the minerals de-
veloped), any change in urine composition leading to a
variation in BRI can indicate a change in the patient's
general metabolic state or disease condition. Therefore,
the BRI can facilitate finding therapies targeted to the in-
dividual patient's metabolism.
Analysis of difficult-to-obtain or expensively-to-determine
biochemical parameters may be avoided if a clinically
relevant correlation between BRI and the course of a
disease can be established. Clinical studies to systemat-
ically investigate BRI, e.g. in patients with bone diseases
like osteoporosis, are planned.
Urinary crystal formation within a point-of-care test
represents a strategy for rapid (downstream) analysis to
detect early stages or progression of metabolic diseases. If
necessary, detailed analysis of (cost- and time-intensive)
individual parameters can be performed in a second step
to complement the BRI-based diagnosis.
The proposed strategy to analyse a person's state in re-
spect to a particular metabolic disease by specific inves-
tigation of his/her urine's tendency to form crystals by
forced growth of a mineral species can be termed ‘urina-
lytiXX’, derived from ‘urine analytics by crystallisation’,
where ‘XX’ stands for ‘crystallisation’—an often used ab-
breviation in the field of geosciences.
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